Could Active Surveillance Without Intervention Be an Option for Intermediate-Risk Prostate Cancer?

A study published by the American Society of Clinical Oncology showed that some patients with intermediate-risk prostate cancer may be suitable for active surveillance.
Although prostate cancer is among the most common cancers and leading cancer causes of death in men, early diagnosis and appropriate treatment produce very successful results. Naturally, as with every cancer, treatment varies by stage. For localized prostate cancer that has not spread to distant tissue, options include surgical removal, radiotherapy, and active surveillance. However, it is inappropriate to state definitively that one is ideal, because prostate cancer treatment is a personal decision and the patient and physician should decide together on the most suitable option. This requires close attention to all developments in these methods.
Active surveillance involves no intervention while the disease does not progress, with close monitoring through regular checkups. Clinical studies showing survival rates close to surgery and radiotherapy in low-risk prostate cancer have made it a widely accepted standard approach in this group. Alongside their survival advantages, radiotherapy and surgery have side effects directly affecting quality of life. Active surveillance has therefore recently been considered not only for low-risk but also intermediate-risk prostate cancer. A study comparing overall survival in low- and intermediate-risk patients undergoing active surveillance was recently presented at the Genitourinary Cancers Symposium.
The study included 237 intermediate-risk and 708 low-risk patients, totaling 945 prostate cancer patients managed with active surveillance, and assessed their 10- and 15-year survival. At 10 years, survival was approximately %83 in the low-risk group and %68 in the intermediate-risk group; at 15 years, it was %69 and %50 respectively. Thus, survival with active surveillance was significantly lower in the intermediate-risk group than in the low-risk group.
However, another recently published study divided intermediate-risk patients into favorable and unfavorable intermediate-risk groups. With active surveillance following brachytherapy (a type of radiotherapy), the low-risk and favorable intermediate-risk groups had similar survival rates.
In conclusion, active surveillance generally appears unsuitable for intermediate-risk prostate cancer, although some patients in this group may be suitable. We anticipate that treatment decisions for intermediate-risk prostate cancer may in future evaluate this group by dividing it into 2 subgroups, and we will continue to follow all developments closely.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.